As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
25 Analysts have issued a BridgeBio Pharma Inc forecast:
25 Analysts have issued a BridgeBio Pharma Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 354 354 |
62%
62%
|
|
| Gross Profit | 339 339 |
57%
57%
|
|
| EBITDA | -590 -590 |
12%
12%
|
|
| EBIT (Operating Income) EBIT | -595 -595 |
12%
12%
|
|
| Net Profit | -797 -797 |
82%
82%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
| Head office | United States |
| CEO | Neil Kumar |
| Employees | 728 |
| Founded | 2015 |
| Website | bridgebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


